Viridian Therapeutics, Inc. VRDN Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s business segments — net loss?
- Viridian Therapeutics, Inc. (VRDN) reported business segments — net loss of -$104.9M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s business segments — net loss changed year-over-year?
- Viridian Therapeutics, Inc.'s business segments — net loss decreased by 20.7% year-over-year, from -$86.91M to -$104.9M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s business segments — net loss has grown at a 38.2% compound annual growth rate (CAGR), from -$129.87M to -$342.6M.
- What does business segments — net loss mean?
- This metric represents the bottom-line financial result for the business segment, calculated as total revenues minus total expenses. For clinical-stage biopharmaceutical companies, this typically reflects the net cash burn required to fund ongoing research and development efforts. It is a primary indicator of the segment's financial sustainability and the pace at which it consumes capital.